インスリンバイオシミラーの世界市場レポート 2025年

インスリンバイオシミラーの市場規模は今後数年で急成長が見込まれます。2029年には61億7,000万米ドルに成長し、CAGRは15.0%となります。予測期間の成長は、世界的な糖尿病の増加、新興市場とアクセス拡大、バイオシミラー採用政策、手頃な価格に対する患者の嗜好、バイオ医薬品業界における共同研究やパートナーシップに起因すると考えられます。予測期間の主な動向には、インスリン製剤ポートフォリオの多様化、世界市場への浸透、インスリンデリバリーにおける技術統合、バイオシミラー開発に対する規制当局の支援、製品開発における患者中心のアプローチなどがあります。

糖尿病有病率の増加は、今後のインスリンバイオシミラー市場の成長を牽引すると予想されます。糖尿病は、血糖値の高止まりを特徴とする慢性代謝疾患です。バイオシミラー医薬品は糖尿病治療に不可欠であり、インスリン治療の代替となるため、糖尿病患者の増加に伴いインスリンバイオシミラーの需要が増加しています。例えば、2023年7月、生物医学およびゲノム情報へのアクセスを提供する米国政府機関National Center for Biotechnology Informationは、2021年に10.5％であった糖尿病有病率が、2030年には11.3％に、さらに2040年には12.2％に増加する見込みであると報告しました。このように、糖尿病有病率の上昇がインスリンバイオシミラー市場の成長を促進しています。

ヘルスケア支出の増加は、インスリンバイオシミラー市場の成長を促進すると予想されます。ヘルスケア支出は、特定の時間枠内でのヘルスケア商品とサービスに対する総支出を表し、インスリンバイオシミラーに大きく影響され、費用対効果の高い代替手段を提供し、全体的なコスト削減に貢献します。例えば、2023年9月のメディケア＆メディケイドサービスセンターによると、2022～2031年までの国民医療費（NHE）の平均成長率の予測値は、GDPの平均成長率を上回ると予想されています。この成長予測により、国内総生産（GDP）に占める医療費の割合は2021年の18.3%から2031年には19.6%に増加し、インスリンバイオシミラー市場を牽引することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のインスリンバイオシミラー市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のインスリンバイオシミラー市場：成長率分析
• 世界のインスリンバイオシミラー市場の実績：規模と成長、2019～2024年
• 世界のインスリンバイオシミラー市場の予測：規模と成長、2024～2029年、2034年
• 世界のインスリンバイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインスリンバイオシミラー市場：バイオシミラーの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 即効性バイオシミラー
• 長期作用型バイオシミラー
• 混合型バイオシミラー
• 世界のインスリンバイオシミラー市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 1型糖尿病
• 2型糖尿病
• 世界のインスリンバイオシミラー市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のインスリンバイオシミラー市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 外来手術センター
• その他
• 世界のインスリンバイオシミラー市場：即効性バイオシミラーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• インスリンアスパルトバイオシミラー
• インスリンリスプロバイオシミラー
• インスリングルリジンバイオシミラー
• 世界のインスリンバイオシミラー市場：長期作用型バイオシミラーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• インスリングラルギンバイオシミラー
• インスリンデテミルバイオシミラー
• インスリンデグルデクバイオシミラー
• 世界のインスリンバイオシミラー市場：混合型バイオシミラーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• インスリンアスパルトプロタミンバイオシミラー
• インスリンリスプロプロタミンバイオシミラー
• 二相性インスリンバイオシミラー

第7章 地域別・国別分析

• 世界のインスリンバイオシミラー市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のインスリンバイオシミラー市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インスリンバイオシミラー市場：競合情勢
• インスリンバイオシミラー市場：企業プロファイル
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mylan N.V.
• Wockhardt Limited
• NOVO Nordisk A/S
• Sanofi S.A
• Fresenius Kabi AG
• Sandoz International GmbH
• Novartis International AG
• Aurobindo Pharma Ltd.
• Intas Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Ltd.
• Samsungbioepis Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Stada Arzneimittel AG
• Celltrion Inc.
• Fujifilm Kyowa Kirin Biologics Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インスリンバイオシミラー市場2029年：新たな機会を提供する国
• インスリンバイオシミラー市場2029年：新たな機会を提供するセグメント
• インスリンバイオシミラー市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Insulin biosimilars denote biological products that closely resemble an existing reference insulin product in terms of quality, safety, and efficacy, which has already received approval and been introduced to the market. Widely employed to regulate blood glucose levels, insulin is indispensable for individuals managing diabetes to sustain healthy glucose levels.

The primary types of biosimilar insulin include rapid-acting biosimilars, long-acting biosimilars, and premixed-acting biosimilars. Rapid-acting biosimilars constitute a category of insulin biosimilar products engineered for swift onset of action and a relatively brief duration of activity. These biosimilars address various disease indications such as type I diabetes and type II diabetes, and they are distributed through diverse channels, including hospital pharmacies, retail pharmacies, and online pharmacies. The end-users encompass hospitals, ambulatory surgical centers, and other entities.

The insulin biosimilars market research report is one of a series of new reports from The Business Research Company that provides insulin biosimilars market statistics, including insulin biosimilars industry global market size, regional shares, competitors with an insulin biosimilars market share, detailed insulin biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the insulin biosimilars industry. This insulin biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin biosimilars market size has grown rapidly in recent years. It will grow from$3.04 billion in 2024 to $3.53 billion in 2025 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to increased diabetes prevalence, growing healthcare costs, expanding access to diabetes treatment, market competition and price pressures, regulatory support and approval pathways

The insulin biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to global diabetes burden, emerging markets and access expansion, biosimilar adoption policies, patient preference for affordability, collaborations and partnerships in biopharmaceutical industry. Major trends in the forecast period include diversification of insulin product portfolios, global market penetration, technology integration in insulin delivery, regulatory support for biosimilars development, patient-centric approaches in product development.

The growing prevalence of diabetes is anticipated to drive the growth of the insulin biosimilars market in the future. Diabetes encompasses a group of chronic metabolic disorders marked by prolonged high blood sugar levels. Biosimilars are essential in diabetes treatment, offering an alternative for insulin therapy, which increases the demand for insulin biosimilars as diabetes cases rise. For example, in July 2023, the National Center for Biotechnology Information, a U.S. government organization that provides access to biomedical and genomic information, reported that the prevalence of diabetes, which was 10.5% in 2021, is expected to increase to 11.3% by 2030 and further to 12.2% by 2040. Thus, the rising prevalence of diabetes is propelling the growth of the insulin biosimilars market.

The upward trajectory of healthcare expenditure is expected to fuel the growth of the insulin biosimilars market. Healthcare expenditure, representing the total spending on healthcare goods and services within a specific timeframe, is significantly influenced by insulin biosimilars, offering cost-effective alternatives and contributing to overall cost savings. For instance, according to the Centers for Medicare & Medicaid Services in September 2023, the projected average growth in National Health Expenditure (NHE) between 2022 and 2031 is expected to surpass the average GDP growth rate. This projected growth will result in an increased health spending share of Gross Domestic Product (GDP) from 18.3 percent in 2021 to 19.6 percent in 2031, thus driving the insulin biosimilars market.

Major companies in the insulin biosimilars market are focusing on developing interchangeable insulin to improve patient access, lower healthcare costs, and ensure consistent therapeutic outcomes for diabetes management. Interchangeable insulin plays a vital role in the insulin biosimilars market by increasing patient access to affordable treatments and promoting adherence to therapy. For example, in April 2023, Eli Lilly, a U.S.-based pharmaceutical company, introduced Rezvoglar (insulin glargine-aglr), an insulin glargine biosimilar designed to enhance glycemic control for both pediatric and adult patients with type 1 diabetes, as well as adults with type 2 diabetes. With its interchangeable designation, pharmacists can substitute it for other insulin glargine prescriptions without requiring physician approval, thereby improving patient accessibility. This launch establishes Rezvoglar as the second interchangeable insulin biosimilar in the U.S., fostering competition and affordability in the insulin biosimilars market.

Strategic partnerships have become a notable trend in major companies operating in the insulin biosimilar market, aiming to develop new products and fortify their market positions. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. For instance, in September 2023, Meitheal Pharmaceuticals partnered with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars, including insulin lispro, insulin glargine, and insulin aspart. This collaboration enables Meitheal Pharmaceuticals to broaden its product portfolio and enhance its global reach.

In November 2022, Biocon Biologics acquired Viatris' global biosimilars business for an undisclosed amount, taking over the portfolio of approved and pipeline biosimilar products, as well as dedicated R&D and manufacturing facilities. This strategic acquisition marked a significant milestone for Biocon Biologics, further consolidating its position in the biosimilars market. Viatris, a US-based pharmaceutical company specializing in insulin biosimilars, was the acquired entity.

Major companies operating in the insulin biosimilars market include Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck & Co Inc., Pfizer Inc., Biocon Ltd., Mylan N.V., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A, Fresenius Kabi AG, Sandoz International GmbH, Novartis International AG, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Samsungbioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Celltrion Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Green Cross Corporation, Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifescience Ltd.

North America was the largest region in the insulin biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in the insulin biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the insulin biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The insulin biosimilar market consists of sales of a variety of insulin types such as intermediate insulin, insulin glargine, and insulin analog. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Insulin biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insulin biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for insulin biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The insulin biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Biosimilars Type: Rapid Acting biosimilars; Long Acting biosimilars; Premixed Acting biosimilars
• 2) By Disease Indication Type: Type I Diabetes; Type II Diabetes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End User: Hospitals; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Rapid Acting Biosimilars: Insulin Aspart Biosimilars; Insulin Lispro Biosimilars; Insulin Glulisine Biosimilars
• 2) By Long Acting Biosimilars: Insulin Glargine Biosimilars; Insulin Detemir Biosimilars; Insulin Degludec Biosimilars
• 3) By Premixed Acting Biosimilars: Insulin Aspart Protamine Biosimilars; Insulin Lispro Protamine Biosimilars; Biphasic Insulin Biosimilars
• Companies Mentioned: Eli Lilly and Company; Boehringer Ingelheim GmbH; Merck & Co Inc.; Pfizer Inc.; Biocon Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Insulin biosimilars Market Characteristics

3. Insulin biosimilars Market Trends And Strategies

4. Insulin biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Insulin biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Insulin biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Insulin biosimilars Market Growth Rate Analysis
• 5.4. Global Insulin biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Insulin biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Insulin biosimilars Total Addressable Market (TAM)

6. Insulin biosimilars Market Segmentation

• 6.1. Global Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid Acting biosimilars
• Long Acting biosimilars
• Premixed Acting biosimilars
• 6.2. Global Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type I Diabetes
• Type II Diabetes
• 6.3. Global Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Other End Users
• 6.5. Global Insulin biosimilars Market, Sub-Segmentation Of Rapid Acting Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Aspart Biosimilars
• Insulin Lispro Biosimilars
• Insulin Glulisine Biosimilars
• 6.6. Global Insulin biosimilars Market, Sub-Segmentation Of Long Acting Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Glargine Biosimilars
• Insulin Detemir Biosimilars
• Insulin Degludec Biosimilars
• 6.7. Global Insulin biosimilars Market, Sub-Segmentation Of Premixed Acting Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Aspart Protamine Biosimilars
• Insulin Lispro Protamine Biosimilars
• Biphasic Insulin Biosimilars

7. Insulin biosimilars Market Regional And Country Analysis

• 7.1. Global Insulin biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Insulin biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Insulin biosimilars Market

• 8.1. Asia-Pacific Insulin biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Insulin biosimilars Market

• 9.1. China Insulin biosimilars Market Overview
• 9.2. China Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Insulin biosimilars Market

• 10.1. India Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Insulin biosimilars Market

• 11.1. Japan Insulin biosimilars Market Overview
• 11.2. Japan Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Insulin biosimilars Market

• 12.1. Australia Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Insulin biosimilars Market

• 13.1. Indonesia Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Insulin biosimilars Market

• 14.1. South Korea Insulin biosimilars Market Overview
• 14.2. South Korea Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Insulin biosimilars Market

• 15.1. Western Europe Insulin biosimilars Market Overview
• 15.2. Western Europe Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Insulin biosimilars Market

• 16.1. UK Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Insulin biosimilars Market

• 17.1. Germany Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Insulin biosimilars Market

• 18.1. France Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Insulin biosimilars Market

• 19.1. Italy Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Insulin biosimilars Market

• 20.1. Spain Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Insulin biosimilars Market

• 21.1. Eastern Europe Insulin biosimilars Market Overview
• 21.2. Eastern Europe Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Insulin biosimilars Market

• 22.1. Russia Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Insulin biosimilars Market

• 23.1. North America Insulin biosimilars Market Overview
• 23.2. North America Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Insulin biosimilars Market

• 24.1. USA Insulin biosimilars Market Overview
• 24.2. USA Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Insulin biosimilars Market

• 25.1. Canada Insulin biosimilars Market Overview
• 25.2. Canada Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Insulin biosimilars Market

• 26.1. South America Insulin biosimilars Market Overview
• 26.2. South America Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Insulin biosimilars Market

• 27.1. Brazil Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Insulin biosimilars Market

• 28.1. Middle East Insulin biosimilars Market Overview
• 28.2. Middle East Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Insulin biosimilars Market

• 29.1. Africa Insulin biosimilars Market Overview
• 29.2. Africa Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Insulin biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Insulin biosimilars Market Competitive Landscape
• 30.2. Insulin biosimilars Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biocon Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Insulin biosimilars Market Other Major And Innovative Companies

• 31.1. Mylan N.V.
• 31.2. Wockhardt Limited
• 31.3. NOVO Nordisk A/S
• 31.4. Sanofi S.A
• 31.5. Fresenius Kabi AG
• 31.6. Sandoz International GmbH
• 31.7. Novartis International AG
• 31.8. Aurobindo Pharma Ltd.
• 31.9. Intas Pharmaceuticals Ltd.
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Samsungbioepis Co. Ltd.
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Stada Arzneimittel AG
• 31.14. Celltrion Inc.
• 31.15. Fujifilm Kyowa Kirin Biologics Co. Ltd.

32. Global Insulin biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Insulin biosimilars Market

34. Recent Developments In The Insulin biosimilars Market

35. Insulin biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Insulin biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Insulin biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Insulin biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer